Natco Pharma gains on launching Pomalidomide Capsules in Canada
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Natco Pharma is currently trading at Rs. 541.15, up by 3.05 points or 0.57% from its previous closing of Rs. 538.10 on the BSE.
The scrip opened at Rs. 548.25 and has touched a high and low of Rs. 548.25 and Rs. 538.90 respectively. So far 709 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 920.00 on 08-Mar-2022 and a 52 week low of Rs. 502.00 on 02-Feb-2023.
Last one week high and low of the scrip stood at Rs. 553.95 and Rs. 530.55 respectively. The current market cap of the company is Rs. 9823.40 crore.
The promoters holding in the company stood at 48.82%, while Institutions and Non-Institutions held 26.65% and 24.53% respectively.
Natco Pharma has launched Pomalidomide Capsules in Canada, the first generic alternative to POMALYST brand in the country approved by Health Canada. Pomalidomide is used in combination with Dexamethasone and Bortezomib for the treatment of adult patients with multiple myeloma. Multiple myeloma, commonly referred to as myeloma, is a cancer of plasma cells. It is the second most common form of blood cancer in Canada with about 8,000 Canadians living with myeloma.
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules and available through the RevAid risk management platform. This launch reflects Natco’s continued investment in Canada to expand portfolio of high-quality generic medicines at affordable prices.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets
